Loading organizations...
HighCape Capital operates as a growth equity fund for innovative Life Sciences companies. It enables businesses in Connected Health, Medical Device/Tool, and Biotechnology to transition into thriving organizations. The firm leverages its veteran, multidisciplinary team for strategic, operational, and commercial support to its portfolio.
Kevin Rakin and Matt Zuga co-founded HighCape Capital in 2013. Rakin, with three decades of life sciences executive and investing experience, notably leading Shire Regenerative Medicine and Advanced BioHealing. Zuga contributes over twenty years in life sciences investment and banking. Their insight formed the firm to fuel promising ventures.
HighCape Capital partners with management teams across its Life Sciences portfolio. Its collaborative model enhances commercial and operational strategies. The firm's mission facilitates company leaders' visions, cultivating successful healthcare enterprises and fostering world-class life sciences entities.
Key people at HighCape Capital.
HighCape Capital was founded in 2013 by Kevin Rakin (Founder and Partner).
Key people at HighCape Capital.
HighCape Capital was founded in 2013 by Kevin Rakin (Founder and Partner).
HighCape Capital has 7 tracked investments across 5 companies. The latest tracked deal is $4.3M Seed in Modifi Bio in October 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 17, 2023 | Modifi Bio | $4.3M Seed | — | Advantage Capital, Lucas DE Breed, Connecticut Innovations, National Brain Tumor Society, Pathway BioVentures, Sontag Foundation |
| Nov 1, 2021 | Wellinks | $25.0M Series C | Stephen Bruso | Connecticut Innovations, Digitalis Ventures, MPM Capital, Benslie International Fund, Stonehenge Capital |
| Jun 20, 2019 | Cybrexa Therapeutics | $13.4M Series B | — | Connecticut Innovations, Cycle Venture Partners |
| Jun 19, 2018 | Zipline Medical | $9.0M Other Equity | Bali Muralidhar | Robert Lake |
| Sep 12, 2017 | Cheetah Medical | $11.8M Series C | — | Fletcher Spaght Ventures, MVM Partners, Robert Bosch Venture Capital, Springfield Investment Management |
| Jun 16, 2017 | Cybrexa Therapeutics | $6.0M Series B | — | Connecticut Innovations |
| Jun 6, 2014 | Cheetah Medical | $5.0M Other Equity | Highcape Capital | — |
